Literature DB >> 21085127

A new c.1621 C > G, p.R541G lamin A/C mutation in a family with DCM and regional wall motion abnormalities (akinesis/dyskinesis): genotype-phenotype correlation.

Lukasz A Małek1, Sarah Labib, Lukasz Mazurkiewicz, Michał Saj, Rafał Płoski, Frédérique Tesson, Zofia T Bilińska.   

Abstract

Mutations in the lamin A/C gene (LMNA) are established causes of familial dilated cardiomyopathy (DCM) with atrio-ventricular block although relatively little is known about genotype-phenotype correlations. We describe a 23-year-old patient who presented with inferolateral wall thinning and akinesis with evidence of mid-myocardial fibrosis on cardiac magnetic resonance. Molecular analysis driven by clinical similarities with a previously described case harboring the p.R541C LMNA mutation revealed a novel c.1621 C > G, p.R541G substitution whose pathogenicity was confirmed by transfection of mouse myoblasts. Our results emphasize the role of LMNA mutations at position R541 in DCM cases with segmental LV wall motion akinesis/dyskinesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21085127     DOI: 10.1038/jhg.2010.137

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  8 in total

1.  Variants of the lamin A/C (LMNA) gene in non-valvular atrial fibrillation patients: a possible pathogenic role of the Thr528Met mutation.

Authors:  Michal Saj; Rafal Dabrowski; Sarah Labib; Agnieszka Jankowska; Malgorzata Szperl; Grazyna Broda; Hanna Szwed; Frederique Tesson; Zofia T Bilinska; Rafal Ploski
Journal:  Mol Diagn Ther       Date:  2012-04-01       Impact factor: 4.074

2.  Inherited dilated cardiomyopathy in a large Moroccan family caused by LMNA mutation.

Authors:  Najlae Adadi; Fatima Zohra Radi; Najim Lahrouchi; Loubna Hara; Ilham Ratbi; Siham Chafai Elalaoui; Marielle Alders; Jamila Zarzur; Connie Bezzina; Abdelaziz Sefiani
Journal:  Anatol J Cardiol       Date:  2018-07       Impact factor: 1.596

3.  Can Circulating Cardiac Biomarkers Be Helpful in the Assessment of LMNA Mutation Carriers?

Authors:  Przemyslaw Chmielewski; Ewa Michalak; Ilona Kowalik; Maria Franaszczyk; Malgorzata Sobieszczanska-Malek; Grazyna Truszkowska; Malgorzata Stepien-Wojno; Elzbieta Katarzyna Biernacka; Bogna Foss-Nieradko; Michal Lewandowski; Artur Oreziak; Maria Bilinska; Mariusz Kusmierczyk; Frédérique Tesson; Jacek Grzybowski; Tomasz Zielinski; Rafal Ploski; Zofia T Bilinska
Journal:  J Clin Med       Date:  2020-05-12       Impact factor: 4.241

4.  Case series: LMNA-related dilated cardiomyopathy presents with reginal wall akinesis and transmural late gadolinium enhancement.

Authors:  Shuai Wang; Daoquan Peng
Journal:  ESC Heart Fail       Date:  2020-07-14

Review 5.  Genotype-phenotype correlation of LMNA variants involving the Arg541 residue: a case report with multimodality imaging and literature review.

Authors:  Andrea Di Marco; María Ruiz-Cueto; Joel Salazar-Mendiguchía; Eduard Claver; Gerard Roura; Paolo Domenico Dallaglio; Ignasi Anguera
Journal:  ESC Heart Fail       Date:  2020-07-15

6.  Phosphorylation of Lamin A/C at serine 22 modulates Nav 1.5 function.

Authors:  Michael A Olaopa; Tomohiko Ai; Bo Chao; Xiangshu Xiao; Matteo Vatta; Beth A Habecker
Journal:  Physiol Rep       Date:  2021-11

7.  LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies.

Authors:  Michal Saj; Zofia T Bilinska; Agnieszka Tarnowska; Agnieszka Sioma; Pierrette Bolongo; Malgorzata Sobieszczanska-Malek; Ewa Michalak; Dorota Golen; Lukasz Mazurkiewicz; Lukasz Malek; Ewa Walczak; Anna Fidzianska; Jacek Grzybowski; Andrzej Przybylski; Tomasz Zielinski; Jerzy Korewicki; Frederique Tesson; Rafal Ploski
Journal:  BMC Med Genet       Date:  2013-05-23       Impact factor: 2.103

8.  Genetic mutation of familial dilated cardiomyopathy based on next‑generation semiconductor sequencing.

Authors:  Xin-Fu Lin; Jie-Wei Luo; Gui Liu; Yao-Bin Zhu; Zhao Jin; Xing Lin
Journal:  Mol Med Rep       Date:  2018-09-05       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.